Market closed
Cogent Biosciences/$COGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Ticker
$COGT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
205
Website
COGT Metrics
BasicAdvanced
$669M
-
-$2.46
0.08
-
Price and volume
Market cap
$669M
Beta
0.08
52-week high
$12.11
52-week low
$3.72
Average daily volume
1.5M
Financial strength
Current ratio
5.322
Quick ratio
5.153
Long term debt to equity
6.205
Total debt to equity
6.815
Management effectiveness
Return on assets (TTM)
-53.78%
Return on equity (TTM)
-99.54%
Valuation
Price to book
4.45
Price to tangible book (TTM)
4.45
Price to free cash flow (TTM)
-2.933
Growth
Earnings per share change (TTM)
2.01%
3-year earnings per share growth (CAGR)
9.67%
What the Analysts think about COGT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.
COGT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
COGT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
COGT News
AllArticlesVideos
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
GlobeNewsWire·1 week ago
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·1 month ago
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cogent Biosciences stock?
Cogent Biosciences (COGT) has a market cap of $669M as of May 04, 2025.
What is the P/E ratio for Cogent Biosciences stock?
The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of May 04, 2025.
Does Cogent Biosciences stock pay dividends?
No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Cogent Biosciences dividend payment date?
Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Cogent Biosciences?
Cogent Biosciences (COGT) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.